20/20 Biolabs Inc
AIDX
7 hedge funds and large institutions have $565K invested in 20/20 Biolabs Inc in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
3.11% more ownership
Funds ownership: 0% → 3.11% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$1.12M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$68.5K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$43.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$35.1K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$4.22K |
Top Sellers
AIDX Hedge Fund Activity: Q1 2026 in Review
7 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in 20/20 Biolabs Inc (AIDX) for Q1 2026, worth a combined $565K.
Buyers outnumbered sellers: 7 funds opened new AIDX positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Cresset Asset Management, opening a new position worth an estimated $1.12M.
- 7 institutional investors held 20/20 Biolabs Inc (AIDX) as of Q1 2026, up from 0 in Q4 2025.
- Funds reported $565K of 20/20 Biolabs Inc stock for Q1 2026.
- 7 funds opened new 20/20 Biolabs Inc positions in Q1 2026 and 0 closed out, a net change of +7 holders.
- The largest 20/20 Biolabs Inc buyer in Q1 2026 was Cresset Asset Management, an estimated $1.12M added.
Based on aggregated 13F filings for Q1 2026.